| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.NBD.2010.05.028 |
| P698 | PubMed publication ID | 20594979 |
| P50 | author | Marios Politis | Q64856266 |
| Clare Loane | Q122914799 | ||
| David J. Brooks | Q38329590 | ||
| Paola Piccini | Q64856193 | ||
| P2093 | author name string | Kit Wu | |
| Lorenzo Kiferle | |||
| Sophie Molloy | |||
| P4510 | describes a project that uses | magnetic resonance imaging | Q161238 |
| MATLAB | Q169478 | ||
| SPSS | Q181596 | ||
| positron emission tomography | Q208376 | ||
| DASB | Q5204319 | ||
| SPM2 | Q41566670 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 216-221 | |
| P577 | publication date | 2010-05-31 | |
| P1433 | published in | Neurobiology of Disease | Q15716606 |
| P1476 | title | Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | |
| P478 | volume | 40 |
| Q64866418 | Q64866418 |
| Q47995478 | 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. |
| Q36972794 | A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. |
| Q92315377 | Atomoxetine and citalopram alter brain network organization in Parkinson's disease |
| Q38603309 | Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders |
| Q36899059 | Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease |
| Q38598375 | Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease |
| Q41566638 | Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients |
| Q34118131 | Clinical application of stem cell therapy in Parkinson's disease |
| Q47952640 | Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. |
| Q43122361 | Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinson's Disease. |
| Q37973611 | Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. |
| Q35664438 | Critical aspects of clinical trial design for novel cell and gene therapies |
| Q87325496 | Depression in Parkinson's disease |
| Q48074706 | Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders--a comparative analysis of in vivo imaging findings |
| Q47998172 | Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey. |
| Q53692679 | Disease progression in LRRK2 parkinsonism. |
| Q92513215 | Dopamine affects short-term memory corruption over time in Parkinson's disease |
| Q35038040 | Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia |
| Q27021464 | Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? |
| Q33761790 | Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? |
| Q38182651 | Dyskinesias in Parkinson's disease: views from positron emission tomography studies |
| Q39075710 | Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. |
| Q35619338 | Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats |
| Q48399270 | Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. |
| Q89533763 | High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort |
| Q38912305 | Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms |
| Q35193033 | Imaging insights into basal ganglia function, Parkinson's disease, and dystonia |
| Q35324977 | Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia |
| Q35264006 | Improving response inhibition in Parkinson's disease with atomoxetine |
| Q33625542 | Improving response inhibition systems in frontotemporal dementia with citalopram |
| Q38199670 | Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. |
| Q55287139 | Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. |
| Q92445892 | L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning |
| Q35054558 | Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease |
| Q57794605 | Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs |
| Q40696539 | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease |
| Q64864744 | Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies. |
| Q37262953 | Molecular imaging as a guide for the treatment of central nervous system disorders |
| Q36724965 | Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease |
| Q31158920 | Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. |
| Q44523798 | Monoaminergic Modulation of Motor Cortex Function |
| Q64948225 | Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update. |
| Q50558839 | Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. |
| Q37499687 | Multiple modes of impulsivity in Parkinson's disease |
| Q30868628 | Neuroimaging in Parkinson disease: from research setting to clinical practice |
| Q34234625 | Neuroimaging: current role in detecting pre-motor Parkinson's disease. |
| Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
| Q64898451 | Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. |
| Q35013240 | Noradrenaline and Parkinson's disease |
| Q39060020 | Parkinson's: a syndrome rather than a disease? |
| Q37980609 | Positron emission tomography imaging in neurological disorders |
| Q37929598 | Positron emission tomography neuroimaging in Parkinson's disease |
| Q36762203 | Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures |
| Q91102329 | Preserved Serotonergic Activity in Early-Onset Parkinson's Disease |
| Q21129423 | Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications |
| Q33731267 | Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis? |
| Q30916063 | Recent imaging advances in neurology. |
| Q35595426 | Recent progress of imaging agents for Parkinson's disease |
| Q36691830 | Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration |
| Q60907864 | Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia |
| Q39407055 | SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias |
| Q37647815 | Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease |
| Q52332824 | Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. |
| Q53188615 | Serotonergic dysfunction in Parkinson's disease and its relevance to disability. |
| Q37092527 | Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease |
| Q55050175 | Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. |
| Q37536347 | Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD |
| Q48345542 | Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. |
| Q37602233 | Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients |
| Q92959120 | Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study |
| Q48300577 | Serotonergic targets for the treatment of L-DOPA-induced dyskinesia. |
| Q38881337 | Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies |
| Q42483704 | Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys |
| Q33921178 | Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart |
| Q39249440 | Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts |
| Q39055550 | Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies |
| Q52582953 | Serotonin, beta-amyloid, and cognition in Parkinson disease. |
| Q37509682 | Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease |
| Q41963193 | The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats |
| Q38182660 | The pathomechanisms underlying Parkinson's disease |
| Q36541032 | The pons and human affective processing--Implications for Parkinson's disease |
| Q47400257 | The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease |
| Q28727519 | The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study |
| Q38118061 | The serotonergic system in motor and non-motor manifestations of Parkinson's disease |
| Q48140796 | Transcranial midbrain sonography and depressive symptoms in patients with Parkinson's disease |
| Q47250613 | Update on Molecular Imaging in Parkinson's Disease. |
Search more.